Pegram Excited for Additional Advances in HER2+ Breast Cancer
Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive...
WHAT'S UP IN
Blind experiment
ESMO 2016: Ribociclib Improves Progression-Free Survival in Advanced Breast Cancer
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved...
